The specific binding ability of EGFR(2R)-lytic hybrid peptide to recombinant EGFR was revealed by a binding assay and biophysical analysis using surface plasmon resonance experiments16, 17, and cytotoxic and anti-tumour effects of EGFR(2R)-lytic hybrid peptide were shown to be stronger than those of the original EGFR-lytic hybrid peptide16. This evidence concerns the gene EGFR and neoplasm.